Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Biotech SPDR (NY: XBI )

94.30 +0.29 (+0.31%)
Official Closing Price Updated: 8:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about S&P Biotech SPDR

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
7 Monster Stock Market Predictions For The Week Of April 25
The week ending April 22 was brutal. The S&P 500 fell by nearly 2.75%, but things were much worse than that. Powell unleashed hell when he noted that a 50 bps rate hike was on the table for the FOMC... 
Via Talk Markets
The “magic Chart” Stock Market (And Sentiment Results)
We have now come to a point Where the market has priced in more rate hikes than are likely to occur. 
Via Talk Markets
4 Undervalued Biotech Stocks to Add to Your Buy List
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns. 
Via InvestorPlace
Healthcare Stocks Lead the Way Up as the Market Fades
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions. 
Via Talk Markets
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. 
Via InvestorPlace
The “Shake It Off” Stock Market (And Sentiment Results)
We may be close to a short term peak in yields – bottom in bonds 
Via Talk Markets
XBI Biotech 15% Potential
The Biotech Sector ETF had a very nice rally, a bull flag, and ended up having the second half of the move to the upside. 
Via Talk Markets
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. 
Via InvestorPlace
Sunshine Biopharma Stock Triples on Positive mRNA Cancer Treatment Results
SBFM stock tripled to $6.53 on Tuesday after revealing that two of its newly designed mRNA molecules are effective in destroying cancer cells. 
Via InvestorPlace
Good Entry Point for Biotech Stocks
Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms. 
Via Talk Markets
CNBC's Final Call: Newmont, Biotech ETF And This Energy Stock
On CNBC's "The Final Call," Carter Worth recommended Newmont Corporation (NYSE: NEM). The stock has jumped almost 36% year to date. 
Via Benzinga
Acadia: Helping With Alzheimers And Parkinsons
Things always change fast in biotech, but until recently things have been moving consistently to the downside. It’s been a while, but we believe this is finally over. And we believe Acadia... 
Via Talk Markets
Top 10 Investment Themes For 2022
What are the investment trends going to look like for 2022? 
Via Talk Markets
Biotech Funds and ETFs Continue to Lag
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are... 
Via Talk Markets
How do Biotechnology Funds and ETFs Perform Over Five Years?
Biotech investing can be difficult for short-term traders but can offer good returns over five years if balanced with other healthcare positions like the XLV. 
Via Talk Markets
AskSlim Market Week - Friday, March 18
Technical and cycle analysis, and market commentary. 
Via Talk Markets
3 Market ETF Stocks to Buy This Week on Fed Jitters
The bears have two major tailwinds and the Fed is one. Here are 3 ETF stocks to buy into a potential relief rally after the event blows over. 
Via InvestorPlace
Tough Slogging Ahead for Investors, Diversification is Important
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature. 
Via InvestorPlace
3 Desirable Drug Stocks With Very Promising Pipelines
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider. 
Via InvestorPlace
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
The Dean Martin, “You’re Nobody ‘Till Somebody Loves You” Stock Market (And Sentiment Results)…
China Tech (Alibaba) and Biotech have been the two least-loved sectors in recent weeks, but we believe this is changing. 
Via Talk Markets
Small Cap Biotech Stocks: Is it time to start trading?
It’s time to trade beaten-up small cap biotech stocks. 
Via Talk Markets
3 Pharma Stocks Yielding Over 3%
The Pharma industry faced headwinds in 2021 as hospitals delayed procedures and elective surgeries. 
Via Talk Markets
9 Monster Stock Market Predictions – The Week Of Jan. 17
The chart for the SPX is looking more and more like a diamond pattern. 
Via Talk Markets
3 Biotech Stocks to Buy That Are Under Severe Pressure
The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom. 
Via InvestorPlace
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
Whitney Tilson Names Cannabis ETF 'Favorite Pick For 2022' But Clock Is Ticking To Change US Regulations
It was another brutal year for cannabis stock investors in 2021 as the U.S. made very little regulatory progress on cannabis reform measures. Fortu... 
Via Benzinga
Fear & Greed In The Biotech Sector
With rates rising, widespread tax-loss selling, and fund manager’s either closing the books for 2021 or just closing down altogether, the market has entered a major risk off phase and biotech stocks... 
Via Talk Markets
Healthcare Stocks Are Winners And Provide Diversification To Your Portfolio
As we have written their year many times speculative small cap biotechs have not done well in 2021 since they peaked in February. 
Via Talk Markets
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.